'Specifically, pembrolizumab is intended for patients with recurrent locally advanced or metastatic stomach cancer or cancer of the part of the esophagus (the tube that connects the throat with the stomach) that connects to the stomach (gastroesophageal junction adenocarcinoma) whose cancer tests positive for the protein PD-L1 and has progressed despite treatment with two or more systemic therapies.'
#Immunology #Immunotherapy
https://www.aacr.org/patients-caregivers/progress-against-cancer/immunotherapy-stomach-cancer-pembrolizumab-keytruda/